2. Cell Cycle/DNA Damage Apoptosis
  3. Topoisomerase Apoptosis
  4. YCJ-02

YCJ-02 is a selective Topoisomerase I (Top I) inhibitor. YCJ-02 can inhibit cell proliferation and induce apoptosis and G2/M phase arrest. YCJ-02 can induce DNA damage and increaseγ-H2AX levels. YCJ-02 can promote Top I deqradation via a ubiquitin/26S proteasome pathway. YCJ-02 increases the expressions of pro-apoptotic proteins Bad, Bax, and cleaved caspase-3. YCJ-02 shows broad-spectrum antitumor activity. YCJ-02 can be used for the research of cancer, such as intrahepatic cholangiocarcinoma (ICC).

For research use only. We do not sell to patients.

YCJ-02

YCJ-02 Chemical Structure

CAS No. : 2260557-09-1

Size Stock
50 mg   Get quote  
100 mg   Get quote  
250 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

YCJ-02 Related Antibodies

Top Publications Citing Use of Products

View All Topoisomerase Isoform Specific Products:

View All Isoforms
Topoisomerase Topo I Topo II

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

YCJ-02 is a selective Topoisomerase I (Top I) inhibitor. YCJ-02 can inhibit cell proliferation and induce apoptosis and G2/M phase arrest. YCJ-02 can induce DNA damage and increaseγ-H2AX levels. YCJ-02 can promote Top I deqradation via a ubiquitin/26S proteasome pathway. YCJ-02 increases the expressions of pro-apoptotic proteins Bad, Bax, and cleaved caspase-3. YCJ-02 shows broad-spectrum antitumor activity. YCJ-02 can be used for the research of cancer, such as intrahepatic cholangiocarcinoma (ICC)[1].

IC50 & Target[1]

Topoisomerase I

 

In Vitro

YCJ-02 shows antitumor activities in HepG2, HuCCT1, BXPC-3, SW1990, HCT-116, SW480, A2780, HeLa, and MCF-7 cells with IC50 values of 0.025, 0.079, 1.15, 0.20, 0.16, 0.12, 0.25, 0.79, and 1.08 μM, respectively[1].
YCJ-02 inhibits proliferation in human HuCCT1, RBE, QBC-939, and mouse A/N, B/R ICC cells with IC50 values of 0.079, 0.31, 0.35, 1.51, and 2.68 μM, respectively[1].
YCJ-02 (0.25-1 μM, 72 h) inhibits colony formation in QBC-939 and HuCCT1 cells[1].
YCJ-02 (0.25-1 μM, 24-48 h) induces G2/M phase arrest and apoptosis in QBC-939 and HuCCT1 cells[1].
YCJ-02 (0.05-0.8 μM) dose-dependently inhibits the Top I enzyme activity and exhibits minimal inhibitory activity against Top II[1].
YCJ-02 (0.125-1 μM, 48 h) reduces Top I levels in QBC-939 and HuCCT1 cells[1].
YCJ-02 (0.125-1 μM, 48 h) induces DNA damage[1].
YCJ-02 (0.125-1 μM) reduced the levels of AKT, p-AKTser473, mTORC1, p-mTORC1ser2448, and Notch1 (NICD) in QBC-939 and A/N cells[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

YCJ-02 Related Antibodies

Apoptosis Analysis[1]

Cell Line: QBC-939 and HuCCT1 cells
Concentration: 0.25, 0.5 and 1μM
Incubation Time: 24 and 48 h
Result: Increased apoptotic rates.
Upregulated levels of p21, p53 and Bcl-2.

Western Blot Analysis[1]

Cell Line: QBC-939 and HuCCT1 cells
Concentration: 0.125, 0.25, 0.5 and 1μM
Incubation Time: 48 h
Result: Reduced Top I levels.

Immunofluorescence[1]

Cell Line: QBC-939 cells
Concentration: 0.125, 0.25, 0.5 and 1μM
Incubation Time: 12 h
Result: Reduced Top I levels.
Increased γ-H2AX levels.
In Vivo

YCJ-02 (10 mg/kg, i.p., 2 weeks for 10 times) inhibits tumor growth and prolongs survival in AKT/NICD-induced primary ICC mice models[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: AKT/NICD-induced primary ICC mice models[1]
Dosage: 10 mg/kg
Administration: Intraperitoneally injection, 2 weeks for 10 times
Result: Reduced tumor volume and prolonged survival.
Had no significant body weight loss.
Decreased tumor area.
Reduced the positive cell rates of CK19 and Ki-67.
Reduced Top I levels and increased the levels of p21, p53, cleaved caspase 3, and γ-H2AX.
Reduced p-AKTser473, mTORC1, p-mTORC1ser2448, and Notch1 (NICD).
Molecular Weight

423.41

Formula

C23H19F2N3O3
CAS No.
SMILES

O=C1C2=CC(F)=C(C=C2C3=C(N1CCN4CCCC4)C5=CC6=C(OCO6)C=C5N=C3)F
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

YCJ-02 Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

YCJ-022260557-09-1YCJ02YCJ 02TopoisomeraseApoptosisTop IDNAγ-H2AXICCQBC-939HuCCT1Inhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
YCJ-02
Cat. No.:
HY-175700
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.